Jazz Pharmaceuticals GAAP EPS of $6.64 beats by $3.75, revenue of $1.2B beats by $30M
Source: SeekingAlpha
2026-02-24 16:17:28 ET
More on Jazz Pharmaceuticals
- 44th Annual J.P. Morgan Healthcare Conference
- Jazz Pharmaceuticals plc (JAZZ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Jazz Pharmaceuticals plc (JAZZ) Discusses HERIZON-GEA-01 Phase III Trial Results for Zanidatamab in HER2+ GEA Transcript
- Jazz Pharmaceuticals Q4 2025 Earnings Preview
- Jazz boasts of first-line Ziihera data in gastroesophageal cancers
Read the full article on Seeking Alpha
For further details see:
Jazz Pharmaceuticals GAAP EPS of $6.64 beats by $3.75, revenue of $1.2B beats by $30M
Jazz Pharmaceuticals plc
NASDAQ: JAZZ
JAZZ Trading
-2.26% G/L:
$183.655 Last:
178,812 Volume:
$185.27 Open:
JAZZ Latest News
February 24, 2026 04:05:00 pm
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
JAZZ Stock Data
$10,064,526,163
58,152,216
1.22%
231
N/A
Biotechnology & Life Sciences
Healthcare
IE
Dublin 4
